Apple Health Outcome

Peptides for glucose

4 compoundsin Regimen’s catalog are configured to track glucose via Apple Health. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.

4 compounds

Semaglutide

GLP-1 Receptor Agonist

GLP-1

A once-weekly GLP-1 receptor agonist for weight management and metabolic health.

  • Significant and sustained weight loss
  • Improved blood sugar regulation
  • Reduced cardiovascular risk markers

Tracks

WeightBMIAppetiteGlucose

Tirzepatide

GIP / GLP-1 Dual Agonist

GLP-1

A once-weekly dual GIP and GLP-1 receptor agonist delivering superior weight loss and metabolic improvements compared to GLP-1 monotherapy.

  • Greater average weight loss vs. semaglutide
  • Improved blood sugar control
  • Reduced appetite and cravings

Tracks

WeightBMIAppetiteGlucose

Liraglutide

GLP-1 Receptor Agonist (Saxenda / Victoza)

GLP-1

Daily injectable GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza, up to 1.8 mg/day) and chronic weight management (Saxenda, up to 3.0 mg/day). Slows gastric emptying, increases satiety, improves glycemic control, and reduces cardiovascular events in T2D.

  • Sustained weight loss
  • A1C reduction in T2D
  • Appetite suppression and reduced food cravings

Tracks

WeightBMIAppetiteGlucose

Insulin

Rapid-Acting Insulin (clinical reference)

Hormone

Pre-dissolved at U-100 concentration (100 IU/mL). Units on a U-100 insulin syringe map 1:1 to draw volume in mL × 100. Insulin is FDA-approved for diabetes management and must be used under medical supervision. Off-label use for nutrient partitioning carries severe hypoglycemia risk and is not recommended.

  • Blood glucose control
  • Postprandial glycemic regulation

Tracks

GlucoseEnergy

Other outcomes